Texas Permanent School Fund Corp Purchases 2,057 Shares of STERIS plc $STE

Texas Permanent School Fund Corp increased its position in shares of STERIS plc (NYSE:STE) by 19.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 12,537 shares of the medical equipment provider’s stock after purchasing an additional 2,057 shares during the period. Texas Permanent School Fund Corp’s holdings in STERIS were worth $3,012,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Spurstone Advisory Services LLC purchased a new position in shares of STERIS during the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. boosted its holdings in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Loomis Sayles & Co. L P bought a new position in STERIS in the 2nd quarter valued at $54,000. Generali Investments Management Co LLC purchased a new stake in STERIS in the second quarter worth $56,000. Finally, CYBER HORNET ETFs LLC bought a new stake in shares of STERIS during the second quarter worth $62,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Up 1.3%

NYSE:STE opened at $254.81 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.37 and a quick ratio of 1.63. STERIS plc has a 1-year low of $200.98 and a 1-year high of $268.60. The company has a 50-day moving average of $252.57 and a 200 day moving average of $244.14. The firm has a market cap of $25.01 billion, a PE ratio of 36.61 and a beta of 1.01.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the business posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, research analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were issued a dividend of $0.63 per share. The ex-dividend date was Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio is currently 36.21%.

Insider Buying and Selling

In other news, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the transaction, the vice president directly owned 5,695 shares in the company, valued at approximately $1,466,747.25. This trade represents a 46.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP John Adam Zangerle sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president directly owned 33,669 shares of the company’s stock, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 25,203 shares of company stock worth $6,624,667 over the last quarter. Insiders own 1.07% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on STE. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, STERIS has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.